- Sagimet Biosciences (SGMT, Financial) to host a virtual KOL event on June 16, 2025, to discuss Phase 3 trial results for acne treatment.
- Denifanstat, a FASN inhibitor, showed positive results in treating moderate to severe acne, meeting all endpoints.
- A Phase 1 trial for TVB-3567, another FASN inhibitor, has been initiated for U.S. acne treatment.
Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company, will hold a virtual Key Opinion Leader (KOL) event on June 16, 2025, at 2:00 PM ET. The event will feature Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego, to discuss the positive outcomes from the Phase 3 clinical trial of denifanstat for treating moderate to severe acne vulgaris in China, conducted by Sagimet’s license partner Ascletis.
The Phase 3 study demonstrated that denifanstat, a once-daily oral small molecule fatty acid synthase (FASN) inhibitor, achieved all primary and secondary endpoints versus placebo with good tolerability. This emphasizes the potential of FASN inhibition as a novel therapeutic mechanism for managing acne, a condition affecting over 50 million individuals in the United States annually.
In addition to presenting the Phase 3 results, Sagimet will discuss the newly started Phase 1 trial for TVB-3567, their second oral FASN inhibitor drug candidate for acne treatment in the U.S. The event will also feature a live Q&A session, with a replay available on Sagimet’s website for 90 days after the event.
For more details on Sagimet’s innovative approaches to addressing acne and metabolic dysfunction, visit their official website at www.sagimet.com.
